Key clinical point: Antiphospholipid antibodies have differing influences on the manifestations of two important autoimmune diseases.
Major finding: Anticardiolipin antibodies conferred the highest risk for arterial thrombosis, she noted (odds ratio, 5.7), whereas lupus anticoagulant conferred the highest risk for venous thrombosis (OR, 4.7).
Study details: Data from 3,651 patients with systemic lupus erythematosus in the RELESSER registry, a multicenter, Spanish hospital-based registry, with retrospective, cross-sectional data collection.
Disclosures: Dr. Riancho Zarrabeitia has received travel grants from AbbVie, Pfizer, UCB, Merck, GlaxoSmithKline, Amgen, and Roche.
Riancho-Zarrabeitia L et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):136-7. Abstract OP0124. doi: 10.1136/annrheumdis-2019-eular.2485.